Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Dermatitis, Contact 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 23Cyclophosphamide 23Whole-Body Irradiation 20Mycophenolic Acid 17Peripheral Blood Stem Cell Transplantation 15Busulfan 14Cyclosporine 12Tacrolimus 10Melphalan 10Antilymphocyte Serum 9Cord Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Methotrexate 6Filgrastim 6Etoposide 6fludarabine 5Methylprednisolone 5Granulocyte Colony-Stimulating Factor 4Vincristine 3Thiotepa 3Sirolimus 3Prednisone 3Methylprednisolone Hemisuccinate 3Methylprednisolone Acetate 3Doxorubicin 3Cytarabine 3Carboplatin 3Alemtuzumab 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Dendritic Cell Sarcoma, Interdigitating × Triamcinolone × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡